Paradigm’s Post

Cranmore Executive Search played a pivotal role in Horizon's rapid and successful expansion into the European market. "I highly recommend Cranmore," says Chris Serafino. "My contact, Chris Sannwald is a very effective partner and helps me not only find the right candidate and fit, but also is patient with me as my needs grow or change." Read the full case study below on how Cranmore's tailored approach to executive search empowered Horizon Therapeutics' European expansion and fuelled their remarkable success! 📈✨ #SuccessStories #ExecutiveSearch #EuropeanExpansion #HorizonTherapeutics

What has your life science career trajectory looked like? It's not one size fits all. Bracken Senior Partner Ina Margaretha Rijnhout offers insights on her own career path. Learn about the necessity for lasting business partnerships, her passion for helping patients, the crucial intersection of leveraging capital for success, and more. Read the blog post here: https://lnkd.in/edGBBPPb #BusinessDevelopment #BiopharmaInvesting #DueDiligence #LifeSci #Bracken

What has your life science career trajectory looked like? It's not one size fits all. Bracken Senior Partner Ina Margaretha Rijnhout offers insights on her own career path. Learn about the necessity for lasting business partnerships, her passion for helping patients, the crucial intersection of leveraging capital for success, and more. Read the blog post here: https://lnkd.in/dDk8FXtK #BusinessDevelopment #BiopharmaInvesting #DueDiligence #LifeSci #Bracken

What has your life science career trajectory looked like? It's not one size fits all. Bracken Senior Partner Ina Margaretha Rijnhout offers insights on her own career path. Learn about the necessity for lasting business partnerships, her passion for helping patients, the crucial intersection of leveraging capital for success, and more. Read the blog post here: https://lnkd.in/gvJfAdr4 #BusinessDevelopment #BiopharmaInvesting #DueDiligence #LifeSci #Bracken

What has your life science career trajectory looked like? It's not one size fits all. Bracken Senior Partner Ina Margaretha Rijnhout offers insights on her own career path. Learn about the necessity for lasting business partnerships, her passion for helping patients, the crucial intersection of leveraging capital for success, and more. Read the blog post here: https://lnkd.in/gZ_K2qxN #BusinessDevelopment #BiopharmaInvesting #DueDiligence #LifeSci #Bracken

We are excited to announce the closing of Cybin’s acquisition of Small Pharma, creating a leading clinical-stage company dedicated to transforming the standard of care for mental health conditions. Together, the combined company has: • The largest, most advanced, well-protected deuterated DMT clinical program • The largest psychedelic IP portfolio, with over 30 patents granted and 160 patents pending • Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy • Four clinical trials expected in 2024 supporting the advancement of the combined pipeline “The closing of this transaction marks a significant milestone in Cybin’s growth trajectory, firmly establishing us as a leader in the psychedelics sector,” said Doug Drysdale, Chief Executive Officer of Cybin. “We welcome the Small Pharma scientists and leaders who are joining the Cybin team, as we look to leverage the many synergies and drive value for shareholders.” Learn more: https://lnkd.in/gfZJeDzk #ChangingMinds #researchanddevelopment #cybin #psychedelicresearch #clinicalresearch #mentalhealthresearch #CybinInc #DrugDevelopment #Biotech #MentalHealth               

Join me on Cut the Chat – Life Science Insider as I share my journey from practicing medicine to becoming the CEO of Avillion LLP. It's been an incredible ride, collaborating with pharma giants and steering innovative projects. Episode 3: Cracking the code: Navigating the Ever-Changing Biotech Landscape In this episode, we discuss strategies to drive success, regulatory compliance, and staying updated on digital innovations. Tune in and let's explore the biotech frontier! https://lnkd.in/ejGZWVdt #LifeScienceJourney #CEOInsights #cutthechat #lifescienceinsider #cutthechatpodcast

An exciting conversation during the Roundtable on "Driving Greater Adoption of Digital Therapeutics into Healthcare Systems" at LSX - partnering for Life Science eXecutives. An exchange stemming from the experiences of pioneers and experts, they discussed the challenges of DTx projects and best practices to scale and maximize their chances for success.   Couldn't attend? Read this guide with 8 tips on how to accelerate and de-risk digital therapeutics projects   https://lnkd.in/eB_WQJHd     #LSXUSA #DTx #HealthTech

Gene&Cell Therapy >> Co-founded by David Baker, Vilya rings in a permanent CEO; Allogene names Eric Schmidt's CFO successor: Cyrus Harmon → Ex-Olema Oncology chief Cyrus Harmon has resurfaced as CEO of Vilya, a Seattle-based macrocycle biotech from David Baker’s lab that raised a $50 million Series A last August. Harmon co-founded Olema in 2007 and he moved into the role of chief technology officer when Sean Bohen was hired as CEO three years ago. He then shifted to chief research officer until Olema restructured in March and laid off about 25% of its staff. CBO Kinney Horn joined Harmon on the chopping block, although Harmon is still on Olema’s board of directors. Former Bristol Myers Squibb exec Nick Meanwell and Arrakis chief innovation officer Jennifer Petter are part of Vilya’s scientific advisory board. Geoffrey Parker → Off-the-shelf cell therapy specialist Allogene has found a CFO. Former Goldman Sachs managing director Geoffrey Parker spent six years at Tricida and was elevated to COO, CFO and EVP in February 2021. Parker succeeds Eric Schmidt, who left Allogene this summer to become a biotech analyst for Cantor Fitzgerald and spoke with Lei Lei Wu as he prepared to dive in to his new gig. Allogene began the year by hiring R&D chief Zachary Roberts and has since picked up chief technical officer Tim Moore and general counsel Earl Douglas. John Tsai → Tom Anderson is out as CEO of Syncona-backed gene therapy maker SwanBio, but he’ll be a strategic advisor and keep his seat on a board that will now be chaired by ex-Novartis medical chief and current Syncona executive partner John Tsai. SwanBio has also recruited Topher Brooke as COO after he spent a year in the same role at Aytu BioPharma. Brooke is the former head of AstraZeneca’s diabetes business unit in North America and co-founded Rumpus Therapeutics, a pediatric disease biotech that was sold to Aytu in 2021. Tsai was just named CEO at another Syncona company, Forcefield Therapeutics, in late September. Richard Daly → AstraZeneca and Takeda alum Richard Daly will replace Patrick McEnany as CEO of Catalyst Pharmaceuticals on Jan. 1, while McEnany will remain chairman of the board. Daly last appeared in this space in January 2022, when he became president of CARsgen’s US subsidiary, CARsgen Therapeutics Corporation. He’s also been COO at BeyondSpring and a board member at Catalyst since 2015. Catalyst previously announced in July that McEnany would step down as chief executive. Michael Rossi → Michael Rossi will take over as president and CEO of Y-mAbs, and once Rossi starts running the biotech on Nov. 6, founder and interim chief Thomas Gad is slated to be vice chairman and CBO. Rossi was general manager of the US business for Novartis’ radiopharma company Advanced Accelerator Applications, and he’s also had a 12-year career with GE Healthcare. Y-mAbs has had a… #lucidquest #genetherapy #celltherapy

As an Advisor to Every Cure, I’m really pleased to share about a few exciting roles (https://lnkd.in/eV6D8rJA), at this Tech-driven, start-up, nonprofit drug development organization that uses machine learning to identify new uses for existing medicines and advances them all the way to patients. Co-Founded by my friends and colleagues David Fajgenbaum, Grant Mitchell, and Tracey Sikora, Every Cure launched one year ago at CGI (https://lnkd.in/erPXpPfQ) to tackle the massive societal problem that the 3,000 FDA-approved medicines are not fully utilized for all of the diseases they can possibly treat. Because of this, patients suffer while treatments hide in plain sight on the pharmacy shelf. With foundational funding from CZI, Elevate Prize, Lyda Hill, Flagship Pioneering, and Arnold Ventures, Every Cure is now searching for high-performing, mission-driven leaders to fill the Chief Medical Officer, Chief Technology Officer, and COO roles along with 7 other positions. Headquarters in NYC and Philadelphia. More details here: https://lnkd.in/eV6D8rJA